phaRNA was founded by scientists for scientists. Our expertise is RNA. We provide GLP mRNA for research and are developing CGMP capability for clinical applications

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

BIOCYTOGEN ENTERS INTO BISPECIFIC ANTIBODY DRUG CONJUGATE AGREEMENT WITH RADIANCE BIOPHARMA

Biocytogen | January 15, 2024

news image

Biocytogen Pharmaceuticals Co., Ltd. a global biotech company focusing on the discovery of novel antibody therapeutics, announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. a biotechnology company specializing in developing next generation Antibody Drug Conjugates. The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for thera...

Read More

Industry Outlook

OPENTRONS PARTNERS WITH ZYMO RESEARCH TO AUTOMATE KEY MICROBIOME CHEMISTRIES ON THE OPENTRONS FLEX™

PRNewswire | June 16, 2023

news image

Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics and Zymo Research Corp, a life science reagent company, are collaborating to transform microbiome and metagenome analysis by fully automating comprehensive, end-to-end workflows from sample collection through library preparation on the Opentrons Flex. Traditional methods of microbiome analysis have provided valuable insights across various applications; however, this approach frequently fa...

Read More

Research

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

news image

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More

Industrial Impact

MODERN MEADOW AND BASF COLLABORATE TO CREATE A NEW INNOVATIVE ANIMAL-FREE ENRICHED MATERIAL

PRnewswire | July 05, 2023

news image

Modern Meadow, a purpose-driven biotechnology company, is proud to announce its strategic partnership with BASF, a leading global chemical company, to embark on a collaboration to revolutionize the material industry. This strategic collaboration will bring together the cutting-edge biofabrication expertise of Modern Meadow with BASF's renowned Ultramid® Ccycled® material, paving the way for the creation of a modern, sustainable, and animal-free material of the future. ...

Read More
news image

Medical

BIOCYTOGEN ENTERS INTO BISPECIFIC ANTIBODY DRUG CONJUGATE AGREEMENT WITH RADIANCE BIOPHARMA

Biocytogen | January 15, 2024

Biocytogen Pharmaceuticals Co., Ltd. a global biotech company focusing on the discovery of novel antibody therapeutics, announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. a biotechnology company specializing in developing next generation Antibody Drug Conjugates. The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for thera...

Read More
news image

Industry Outlook

OPENTRONS PARTNERS WITH ZYMO RESEARCH TO AUTOMATE KEY MICROBIOME CHEMISTRIES ON THE OPENTRONS FLEX™

PRNewswire | June 16, 2023

Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics and Zymo Research Corp, a life science reagent company, are collaborating to transform microbiome and metagenome analysis by fully automating comprehensive, end-to-end workflows from sample collection through library preparation on the Opentrons Flex. Traditional methods of microbiome analysis have provided valuable insights across various applications; however, this approach frequently fa...

Read More
news image

Research

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More
news image

Industrial Impact

MODERN MEADOW AND BASF COLLABORATE TO CREATE A NEW INNOVATIVE ANIMAL-FREE ENRICHED MATERIAL

PRnewswire | July 05, 2023

Modern Meadow, a purpose-driven biotechnology company, is proud to announce its strategic partnership with BASF, a leading global chemical company, to embark on a collaboration to revolutionize the material industry. This strategic collaboration will bring together the cutting-edge biofabrication expertise of Modern Meadow with BASF's renowned Ultramid® Ccycled® material, paving the way for the creation of a modern, sustainable, and animal-free material of the future. ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us